Is the incidence and prevalence of inhibitors greater with recombinant products? No.
Lusher
J M
JM
Division of Hematology/Oncology, Children's Hospital of Michigan, Detroit, MI 48201, USA. jlusher@med.wayne.edu
D000818:Animals; D001779:Blood Coagulation Factors / Q000276:immunology*; D005169:Factor VIII / Q000235:genetics / Q000276:immunology; D006801:Humans; D015994:Incidence; D007518:Isoantibodies / Q000097:blood*; D007519:Isoantigens / Q000235:genetics; D015995:Prevalence; D011994:Recombinant Proteins / Q000276:immunology*; D012307:Risk Factors
D001779:Blood Coagulation Factors; D007518:Isoantibodies; D007519:Isoantigens; D011994:Recombinant Proteins; D005169:Factor VIII